Recent Updates
Recently added Catalysts

CHI-202,CHI-101

Phase 2

Delayed Onset Muscle Soreness (DOMS) | Unknown | Other |Canopy Growth Corporation Common Shares|Last Updated: Feb 15, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05026164Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical ActivityPHASE2 COMPLETED 40Dec 1, 2021Feb 1, 2022Feb 15, 2022 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
CHI-202DIETARY_SUPPLEMENTBlend of cannabinoids \& other ingredients
CHI-101DIETARY_SUPPLEMENTPlacebo
Unlock Study Design Details